Iovance Biotherapeutics, Inc. NASDAQ:IOVA

Iovance Biotherapeutics stock price today

$2.61
-4.76
-64.59%
Financial Health
0
1
2
3
4
5
6
7
8
9

Iovance Biotherapeutics stock price monthly change

-15.58%
month

Iovance Biotherapeutics stock price quarterly change

-15.58%
quarter

Iovance Biotherapeutics stock price yearly change

+1.94%
year

Iovance Biotherapeutics key metrics

Market Cap
2.27B
Enterprise value
N/A
P/E
-2.34
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
1.81
PEG ratio
0.20
EPS
-1.8
Revenue
1.90M
EBITDA
-447.80M
Income
-449.64M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-23519.12%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Iovance Biotherapeutics stock price history

Iovance Biotherapeutics stock forecast

Iovance Biotherapeutics financial statements

Average Price Target
Last Year

$21.33

Potential upside: 717.36%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Profit margin
Jun 2023 238K -106.52M -44759.66%
Sep 2023 469K -113.76M -24255.86%
Dec 2023 482K -116.37M -24145.02%
Mar 2024 715K -112.97M -15800.84%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Debt to assets
Jun 2023 757293000 178.72M 23.6%
Sep 2023 852315000 178.30M 20.92%
Dec 2023 780351000 195.73M 25.08%
Mar 2024 869830000 189.80M 21.82%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Cash Flow
Jun 2023 -93.95M -156.77M 1.02M
Sep 2023 -84.08M -79.01M 202.8M
Dec 2023 -83.97M -72.84M 962K
Mar 2024 -122.27M -111.50M 193.57M

Iovance Biotherapeutics alternative data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Employee count
Aug 2023 503
Sep 2023 503
Oct 2023 503
Nov 2023 503
Dec 2023 503
Jan 2024 503
Feb 2024 503
Mar 2024 557
Apr 2024 557
May 2024 557
Jun 2024 557
Jul 2024 557

Iovance Biotherapeutics other data

100.00% 0.00%
of IOVA is owned by hedge funds
154.34M -1.46M
shares is hold by hedge funds

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Insider trades (number of shares)
Period Buy Sel
Feb 2024 5282000 0
Nov 2024 0 50000
Transaction Date Insider Security Shares Price per share Total value Source
Option
PURI RAJ K. officer: Chief Regulatory Officer
Restricted Stock Units 8,334 N/A N/A
Option
PURI RAJ K. officer: Chief Regulatory Officer
Common Stock 8,334 N/A N/A
Option
VOGT FREDERICK G director, officer.. Common Stock 10,417 N/A N/A
Option
VOGT FREDERICK G director, officer.. Common Stock 10,417 N/A N/A
Option
VOGT FREDERICK G director, officer.. Restricted Stock Units 10,417 N/A N/A
Option
VOGT FREDERICK G director, officer.. Restricted Stock Units 10,417 N/A N/A
Option
BILINSKY IGOR officer: Chief Operating Officer
Common Stock 3,516 N/A N/A
Option
BILINSKY IGOR officer: Chief Operating Officer
Restricted Stock Units 3,516 N/A N/A
Option
GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me.. Common Stock 3,906 N/A N/A
Option
GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me.. Common Stock 3,906 N/A N/A
Insider Compensation
Mr. Jean-Marc Bellemin M.B.A. (1972) Chief Financial Officer & Principal Accounting Officer
$580,000
Dr. Friedrich Graf Finckenstein M.D. (1967) Chief Medical Officer $551,400
Dr. Frederick G. Vogt Ph.D., Esq. (1974) Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec. $515,400
Friday, 20 December 2024
globenewswire.com
Thursday, 19 December 2024
fool.com
Tuesday, 17 December 2024
fool.com
Thursday, 12 December 2024
fool.com
Saturday, 7 December 2024
fool.com
Wednesday, 27 November 2024
fool.com
Tuesday, 26 November 2024
globenewswire.com
Saturday, 23 November 2024
fool.com
Friday, 22 November 2024
fool.com
Saturday, 16 November 2024
fool.com
Monday, 11 November 2024
seekingalpha.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Thursday, 24 October 2024
fool.com
Friday, 4 October 2024
fool.com
Thursday, 3 October 2024
seekingalpha.com
Thursday, 26 September 2024
fool.com
Monday, 16 September 2024
fool.com
Friday, 6 September 2024
fool.com
Tuesday, 3 September 2024
globenewswire.com
Monday, 2 September 2024
fool.com
Tuesday, 27 August 2024
fool.com
Friday, 16 August 2024
globenewswire.com
Wednesday, 14 August 2024
fool.com
Sunday, 11 August 2024
seekingalpha.com
Friday, 9 August 2024
fool.com
investorplace.com
  • What's the price of Iovance Biotherapeutics stock today?

    One share of Iovance Biotherapeutics stock can currently be purchased for approximately $2.61.

  • When is Iovance Biotherapeutics's next earnings date?

    Unfortunately, Iovance Biotherapeutics's (IOVA) next earnings date is currently unknown.

  • Does Iovance Biotherapeutics pay dividends?

    No, Iovance Biotherapeutics does not pay dividends.

  • How much money does Iovance Biotherapeutics make?

    Iovance Biotherapeutics has a market capitalization of 2.27B.

  • What is Iovance Biotherapeutics's stock symbol?

    Iovance Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "IOVA".

  • What is Iovance Biotherapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Iovance Biotherapeutics?

    Shares of Iovance Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Iovance Biotherapeutics's key executives?

    Iovance Biotherapeutics's management team includes the following people:

    • Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer(age: 53, pay: $580,000)
    • Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer(age: 58, pay: $551,400)
    • Dr. Frederick G. Vogt Ph.D., Esq. Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec.(age: 51, pay: $515,400)
  • How many employees does Iovance Biotherapeutics have?

    As Jul 2024, Iovance Biotherapeutics employs 557 workers.

  • When Iovance Biotherapeutics went public?

    Iovance Biotherapeutics, Inc. is publicly traded company for more then 14 years since IPO on 15 Oct 2010.

  • What is Iovance Biotherapeutics's official website?

    The official website for Iovance Biotherapeutics is iovance.com.

  • Where are Iovance Biotherapeutics's headquarters?

    Iovance Biotherapeutics is headquartered at 825 Industrial Road, San Carlos, CA.

  • How can i contact Iovance Biotherapeutics?

    Iovance Biotherapeutics's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 02607120.

  • What is Iovance Biotherapeutics stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Iovance Biotherapeutics in the last 12 months, the avarage price target is $21.33. The average price target represents a 717.36% change from the last price of $2.61.

Iovance Biotherapeutics company profile:

Iovance Biotherapeutics, Inc.

iovance.com
Exchange:

NASDAQ

Full time employees:

557

Industry:

Biotechnology

Sector:

Healthcare

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

825 Industrial Road
San Carlos, CA 94070

CIK: 0001425205
ISIN: US4622601007
CUSIP: 462260100